VENDOR GOVERNANCE SERVICES
BioBoston CRO provides clinical trial vendor management and governance support for sponsors that need clear operational accountability across CROs, laboratories, technology providers, central services, and specialist vendors. Support can include governance design, deliverable and milestone control, key performance indicators, meeting management, issue and change escalation, cross-vendor dependencies, performance
improvement, transition, or recovery.
Global Reach
Therapeutic Area Coverage
Years of Experience
START A CONVERSATION
Select the support you need and share a few details about your project. We’ll use this information to route your inquiry to the appropriate BioBoston team member.
Please do not submit confidential, patient-identifiable, or proprietary information through this form.
The engagement should be scoped around the current state of the work, the intended decision or milestone, the source package, and the sponsor's approval responsibilities.
Coordinate contracts, responsibilities, deliverables, milestones, data and document handoffs, decisions, metrics, issues, and escalation across the vendor ecosystem.
Move from repeated status escalation to defined evidence, root causes, recovery actions, owners, deadlines, and sponsor decisions.
Control knowledge transfer, data and document custody, open work, systems, responsibilities, financial exposure, continuity, and acceptance criteria.
when needed
Problems
The service is most valuable when the team can identify the specific control gap, decision, deliverable, or
recovery need rather than requesting generic capacity.
Scope
The exact scope depends on the maturity of the work, the quality of the inputs, the sponsor’s procedures,
the review model, and the target milestone.
Deliverables
Deliverables should be confirmed at kickoff and linked to defined sponsor decisions, review cycles, and downstream handoffs.
Client inputs
The sponsor does not need every detail finalized before kickoff, but approved decisions, open questions, source owners, reviewers, and deadlines must be distinguishable.
Process
1. Confirm the purpose, current state, intended use, milestone, stakeholders, responsibilities, systems or vendors, and agreed deliverables.
2. Review available source materials, prior decisions, procedures, evidence, and open issues; issue a focused gap and dependency list.
3. Develop the work plan, specifications, document, assessment, or control package included in scope.
4. Coordinate review through named sponsor and cross-functional decision owners and maintain a controlled open-item and comment process.
5. Perform the agreed technical, quality, consistency, or operational checks and document remaining risks or limitations.
6. Prepare the approved handoff, implementation, submission, remediation, archive, or next-step package as defined in scope.
Considerations
The work should remain proportionate to the risk and intended use, follow the sponsor’s controlled process, and preserve clear sponsor decision authority.
Engagement options
BioBoston leads the defined scope from assessment and planning through drafting or execution, review, quality control, and handoff.
BioBoston addresses a specific section, decision, backlog, finding, vendor issue, or stalled deliverable without expanding the engagement unnecessarily.
BioBoston provides an objective second-line review, oversight role, or embedded specialist while the sponsor or another vendor retains primary execution.
RELATED SERVICES
Maintain sponsor compliance accountability, risk-based verification, oversight evidence, and control of delegated activities.
Reconcile vendor proposals, commitments, invoices, forecasts, change orders, and cost-to-complete with performance and scope.
Integrate vendor schedules, dependencies, milestones, forecasts, delay impacts, and recovery actions.
Stabilize a study when vendor underperformance is part of a broader operational, quality, data, timeline, or financial disruption.
Expertise
Vendor-governance experience should match the study phase, vendor and contract model, outsourced
functions, data and system interfaces, geography, performance issues, and transition or recovery
complexity.
RESOURCES
Explore the following resources for additional insights and information relevant to this service.
A planned template for governance levels, participants, cadence, decisions, records, metrics, escalation, and sponsor oversight interfaces.
A planned guide to definition, data source, threshold, trend, interpretation, owner, action, escalation, and evidence.
A planned checklist for scope, contracts, data, documents, systems, access, open work, quality, finance, knowledge, continuity, and acceptance.
Full-service CRO and FSP models solve different outsourcing problems. This guide helps emerging biotech sponsors determine which model or hybrid combination best matches their internal capabilities, trial complexity, governance capacity, and need for operational control.
Choosing a Phase I CRO requires more than comparing capabilities, timelines, and price. This sponsor due-diligence guide provides a practical framework for evaluating early-phase experience, safety processes, sites and laboratories, data flows, vendor governance, responsibilities, and the team that will actually deliver the study.
FAQs
Support may include governance design, deliverable and milestone control, metrics, meetings, decisions, actions, issues, changes, dependencies, escalation, performance improvement, transition, and sponsor side reporting.
Vendor Governance manages operational performance and delivery. Sponsor Oversight demonstrates compliance accountability and risk-based control over delegated activities. They should coordinate but remain distinct.
Yes. Support may include agenda design, evidence review, decisions, actions, metrics, issues, changes, escalation, minutes, and follow-through within defined sponsor authority.
Yes. The work may include performance assessment, root causes, contractual and operational evidence,
recovery plan, metrics, escalation, executive governance, transition options, and acceptance criteria.
Yes, in coordination with Budget Tracking and sponsor finance, procurement, and legal owners. Commercial decisions remain with the sponsor.
No. It improves clarity, evidence, accountability, decision making, and escalation, but outcomes depend on vendor capability, contracts, resources, study conditions, and sponsor decisions.
PROJECT FORM
Share the study, vendors, services, current governance, key metrics, recurring issues, changes, upcoming milestones, and the support you need. A BioBoston team member will review the request and follow up regarding fit and possible next steps.
Please do not submit confidential, patient-identifiable, or proprietary information through this form.
A productive first discussion identifies vendors, contracts, responsibilities, deliverables, metrics, issues, changes, dependencies, and the next milestone. BioBoston can then define the governance, improvement, transition, or recurring sponsor-side role.
